The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials

Angela Genge; Jesse M. Cedarbaum; Jeremy Shefner; Adriano Chio; Ammar Al-Chalabi; Philip Van Damme; Chris McDermott; Jonathan Glass; James Berry; Ruben P.A. van Eijk; et al.

doi:10.1080/21678421.2024.2320880

Back

The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials

Journal article

Peer reviewed

The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials

Angela Genge, Jesse M. Cedarbaum, Jeremy Shefner, Adriano Chio, Ammar Al-Chalabi, Philip Van Damme, Chris McDermott, Jonathan Glass, James Berry, Ruben P.A. van Eijk, …

Amyotrophic lateral sclerosis and frontotemporal degeneration, Vol.25(3-4), pp.382-387

05/2024

DOI: https://doi.org/10.1080/21678421.2024.2320880

PMID: 38396337

Abstract

Clinical trial design

clinical trial outcome measures

functional rating scale

harmonization

statistical analysis

Files and links (1)

url

https://doi.org/10.1080/21678421.2024.2320880View

Published (Version of record) Open

Metrics

1 Record Views

Details

Title: The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials
Creators: Angela Genge - Montreal Neurological Institute and Hospital
Jesse M. Cedarbaum - The Neurological Institute
Jeremy Shefner - Barrow Neurological Institute
Adriano Chio - University of Turin
Ammar Al-Chalabi - King's College London
Philip Van Damme - KU Leuven
Chris McDermott - University of Sheffield
Jonathan Glass - Emory University
James Berry - Massachusetts General Hospital
Ruben P.A. van Eijk - University Medical Center Utrecht
et al.
Publication Details: Amyotrophic lateral sclerosis and frontotemporal degeneration, Vol.25(3-4), pp.382-387
Number of pages: 6
Grant note: Amylin Pharmaceuticals (http://data.elsevier.com/vocabulary/SciValFunders/100004323)
Identifiers: 991006262285302656
Academic Unit: Neurology
Language: English
Resource Type: Journal article